InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,599.12
(
0.04%
)
US TECH 100
19,211.60
(
0.01%
)
Dow Jones
40,784.57
(
-0.12%
)
Brent Oil
75.98
(
-1.01%
)
Bitcoin
59,436.83
(
0.74%
)
Post# of 252939
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 837
Posts 120316
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 246055

Tuesday, 04/18/2023 1:56:53 PM

Tuesday, April 18, 2023 1:56:53 PM

Post# of 252939
ASBM abandons HBV arena, for all practical purposes:

https://finance.yahoo.com/news/assembly-biosciences-announces-additional-promising-120000883.html

No further internal development will be done on ABI-4344, ASMB’s fourth(!) HBV core inhibitor. ASMB dumped its third HBV core inhibitor, ABI-H3733, a few weeks ago and has yet to do anything right in HBV (see #msg-171513883 and the embedded links there).

According to today’s PR, ASMB’s clinical focus will now be its herpes and HDV programs.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up